槐耳颗粒与索拉菲尼对于小肝癌切除术后的有效性及安全性分析

目的比较小肝癌切除术后服用槐耳颗粒或索拉菲尼的有效性及安全性。方法回顾性搜集我中心小肝癌患者行根治性手术切除后服用槐耳颗粒或索拉菲尼的82例患者,根据术后服用药物的不同分为槐耳颗粒组（51例）及索拉菲尼组（31例）,分析2组患者的术前人口学资料、术前肿瘤学特征及术后资料,比较2组患者的生存率、肿瘤复发率、服药后不良事件等。结果 1 2组患者的人口学资料、肝功能、肿瘤特点比较差异均无统计学意义（P〉0.05）。2槐耳颗粒组和索拉菲尼组的总生存率比较,差异无统计学意义（P=0.737）,无瘤生存率2组间比较差异也无统计学意义（P=0.699）。3肿瘤复发或转移在槐耳颗粒组有19例（37.3%）,而在索拉菲尼组有10例（32.3%）,2组的复发或转移发生率比较,差异无统计学意义（P=0.648）。4槐耳颗粒组共有6例次（5例）出现不良反应,其中恶心伴或不伴呕吐3例,疲劳2例,腹泻1例。索拉菲尼组共发生13例次（11例）不良反应,其中恶心伴或不伴呕吐2例,疲劳2例,腹泻4例,手足综合征2例,脱发1例,皮疹1例,高血压1例。索拉菲尼组不良反应发生率明显高于槐耳颗粒组（35.5%比9.8%,P=0.026）。结论对于已经行根治性切除的小肝癌来讲,槐耳颗粒以其良好的治疗效果及可靠的安全性,可以考虑作为一种有效的术后辅助治疗方法。

Efficacy and Safety of Huaier and Sorafenib in Treatment of Small Hepatocellular Carcinoma Following Radical Resection

Objective To compare the efficacy and safety of Huaier and Sorafenib in treatment of small hepatocellular carcinoma （HCC） following radical resection. Methods Eighty-two patients with small HCC accepted radical liver resection and then taken Huaier or Sorafenib were collected retrospectively. These patients were divided into Huaier group （51 cases） and Sorafenib group （31 cases） according to the different administration drugs after operation. The baseline characteristics, tumor characteristics, survival rate, tumor recurrence rate, and side effects were compared between two groups. Results （1） There were no significant differences on the baseline demographic characteristics, liver function, and tumor characteristics between two groups （.P 〉 0. 05）. （2） The overall survival rate and tumor-free survival rate had no significant differences between the Huaier group and the Sorafenib group （P：0. 737, P：0. 699）. （3） The rate of recurrence or metastasis had no significant difference between the Huaier group and Sorafenib group （37.3% versus 32.3%, P=-0.648）. The most common site of the recurrence or metastasis was the liver and the lung followed. （A） There were only 5 cases suffered side effects after taking Huaier and no case needed Huaier discontinuance. However, 11 cases suffered side effects after taking Sorafenib and 3 cases needed Sorafenib discontinuance, and the rate of the side effect in the Sorafenib group was much higher than that in the Huaier group （35. 5% versus 9. 8%, P=0. 026）. Conclusion For the small HCC who accepted radical liver resection, Huaier seems to be an effective and safe drug.